Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
AssigneeBaxalta Incorporated
InventorsMiranda Chapman, Bruce Ewenstein, Bettina Ploder
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease comprising administering to the subject at least one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
Claims37
-19. (canceled)
A method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease (VWD) comprising administering to the subject two doses of recombinant von Willebrand Factor (rVWF) each ranging from about 40 IU/kg to about 100 IU/kg, wherein the first dose further comprises recombinant Factor VIII (rFVIII).
A method for treating gastrointestinal bleeding in a subject with severe von Willebrand Disease (VWD) comprising administering to the subject one dose of recombinant von Willebrand Factor (rVWF) ranging from about 40 IU/kg to about 100 IU/kg and one dose of recombinant Factor VIII (rFVIII).
Dependencies are inferred from the claim text.